Logo image of DMAC

DIAMEDICA THERAPEUTICS INC (DMAC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DMAC - CA25253X2077 - Common Stock

8.16 USD
-0.19 (-2.28%)
Last: 1/9/2026, 8:00:01 PM
8.16 USD
0 (0%)
After Hours: 1/9/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, DMAC scores 2 out of 10 in our fundamental rating. DMAC was compared to 530 industry peers in the Biotechnology industry. DMAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DMAC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DMAC had negative earnings in the past year.
DMAC had a negative operating cash flow in the past year.
DMAC had negative earnings in each of the past 5 years.
In the past 5 years DMAC always reported negative operating cash flow.
DMAC Yearly Net Income VS EBIT VS OCF VS FCFDMAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

DMAC has a Return On Assets of -55.96%. This is comparable to the rest of the industry: DMAC outperforms 44.91% of its industry peers.
Looking at the Return On Equity, with a value of -61.85%, DMAC is in the better half of the industry, outperforming 60.19% of the companies in the same industry.
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
DMAC Yearly ROA, ROE, ROICDMAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

DMAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAC Yearly Profit, Operating, Gross MarginsDMAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, DMAC has more shares outstanding
DMAC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DMAC has a worse debt to assets ratio.
DMAC Yearly Shares OutstandingDMAC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DMAC Yearly Total Debt VS Total AssetsDMAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

DMAC has an Altman-Z score of 43.20. This indicates that DMAC is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 43.20, DMAC belongs to the top of the industry, outperforming 96.04% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that DMAC is not too dependend on debt financing.
The Debt to Equity ratio of DMAC (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 43.2
ROIC/WACCN/A
WACCN/A
DMAC Yearly LT Debt VS Equity VS FCFDMAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 10.67 indicates that DMAC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.67, DMAC belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.
DMAC has a Quick Ratio of 10.67. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.67, DMAC belongs to the best of the industry, outperforming 83.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.67
Quick Ratio 10.67
DMAC Yearly Current Assets VS Current LiabilitesDMAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

DMAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.79%.
EPS 1Y (TTM)-26.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.64% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.28%
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%
EPS Next 5Y-2.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMAC Yearly Revenue VS EstimatesDMAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
DMAC Yearly EPS VS EstimatesDMAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DMAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DMAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAC Price Earnings VS Forward Price EarningsDMAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAC Per share dataDMAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

DMAC's earnings are expected to decrease with -14.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%

More info and screens

0

5. Dividend

5.1 Amount

DMAC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DIAMEDICA THERAPEUTICS INC

NASDAQ:DMAC (1/9/2026, 8:00:01 PM)

After market: 8.16 0 (0%)

8.16

-0.19 (-2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners22.78%
Inst Owner Change0%
Ins Owners10.8%
Ins Owner Change0.74%
Market Cap424.97M
Revenue(TTM)N/A
Net Income(TTM)-31.93M
Analysts81.82
Price Target15.81 (93.75%)
Short Float %17.67%
Short Ratio11.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.48%
Min EPS beat(2)-4.17%
Max EPS beat(2)7.12%
EPS beat(4)2
Avg EPS beat(4)0.65%
Min EPS beat(4)-4.17%
Max EPS beat(4)7.12%
EPS beat(8)6
Avg EPS beat(8)5.09%
EPS beat(12)9
Avg EPS beat(12)3.21%
EPS beat(16)13
Avg EPS beat(16)10.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25.68%
PT rev (3m)25.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.23
P/tB 8.23
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.67
Quick Ratio 10.67
Altman-Z 43.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)156.03%
Cap/Depr(5y)156.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y-16.28%
EPS Next 2Y-13.37%
EPS Next 3Y-14.37%
EPS Next 5Y-2.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.98%
EBIT Next 3Y-21.87%
EBIT Next 5YN/A
FCF growth 1Y-56.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.83%
OCF growth 3YN/A
OCF growth 5YN/A

DIAMEDICA THERAPEUTICS INC / DMAC FAQ

What is the ChartMill fundamental rating of DIAMEDICA THERAPEUTICS INC (DMAC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DMAC.


What is the valuation status of DIAMEDICA THERAPEUTICS INC (DMAC) stock?

ChartMill assigns a valuation rating of 0 / 10 to DIAMEDICA THERAPEUTICS INC (DMAC). This can be considered as Overvalued.


What is the profitability of DMAC stock?

DIAMEDICA THERAPEUTICS INC (DMAC) has a profitability rating of 1 / 10.


What is the expected EPS growth for DIAMEDICA THERAPEUTICS INC (DMAC) stock?

The Earnings per Share (EPS) of DIAMEDICA THERAPEUTICS INC (DMAC) is expected to decline by -16.28% in the next year.